

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934  
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person * <u>Gonsalves Daniel</u>  (Last) (First) (Middle) <u>C/O BIONIK LABORATORIES CORP.</u> <u>80 COOLIDGE HILL ROAD</u>  (Street) <u>WATERTOWN MA</u> <u>02472</u>  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>10/06/2022</u>	3. Issuer Name and Ticker or Trading Symbol <u>Bionik Laboratories Corp.</u> [ <u>BNKL</u> ]	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Executive Vice President &amp; CFO</u>	
		5. If Amendment, Date of Original Filed (Month/Day/Year)	
		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	--	--	--

Table II - Derivative Securities Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Stock Option (Right to Buy)</u>	<u>10/14/2021</u> <sup>(1)</sup>	<u>10/14/2028</u>	<u>Common Stock</u>	<u>25,000</u>	<u>2.1</u>	<u>D</u>	
<u>Stock Option (Right to Buy)</u>	<u>10/06/2023</u> <sup>(2)</sup>	<u>10/06/2029</u>	<u>Common Stock</u>	<u>60,000</u>	<u>0.302</u>	<u>D</u>	

Explanation of Responses:

1. The option vests as to 6,250 underlying shares on the grant date of October 14, 2021, and each yearly anniversary thereafter. All 25,000 shares underlying the option will vest, subject to earlier termination in accordance with the terms of the option, on October 14, 2024.
2. The option vests 1/3 on each of the first three anniversaries of the grant date of October 6, 2022. All 60,000 shares underlying the option will vest, subject to earlier termination in accordance with the terms of the option, on October 6, 2025.

/s/ Daniel Gonsalves 10/25/2022  
\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.